1,298 material Form 8-K filings that 1,057 companies we cover made with the SEC in April 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On April 9, 2026, EOG updated its first quarter 2026 guidance for current tax expense, raising it to $500 million-$600 million from the $230 million-$330 million range it gave on February 24, 2026. EOG said higher crude oil prices in the first quarter, and those expected for the full year, tied to the Middle East conflict drove the change. EOG is not updating any other first quarter or full year 2026 guidance ranges from February.
Q1 2026 current tax expense guidance now $500 million-$600 million, up from $230 million-$330 million.
EOG cited higher crude oil prices realized in Q1 2026 and anticipated for full year 2026 due to the Middle East conflict.
NYMEX West Texas Intermediate crude averaged $72.17 per barrel and Henry Hub natural gas averaged $4.96 per million British thermal units in Q1 2026.
EOG paid net cash of $53 million to settle financial commodity derivative contracts in Q1 2026; no other guidance ranges were updated.
On April 9, 2026, Chevron gave preliminary first-quarter 2026 estimates that mix higher oil and gas prices with several negative items. Higher commodity prices are expected to add $1.6 billion to $2.2 billion to upstream earnings versus fourth quarter 2025, but timing effects and a litigation charge are expected to weigh on earnings and cash flow. Final results are due on or around May 1, 2026, and the figures are unaudited and could change.
Timing effects, after tax, are expected to reduce first-quarter earnings and cash flow from operations excluding working capital by about $2.7 billion to $3.7 billion, mostly in Downstream.
Upstream earnings are expected to benefit by $1.6 billion to $2.2 billion from higher commodity prices compared with fourth quarter 2025.
A Downstream litigation reserve tied to ceased operations is expected to bring a charge of about $350 million to $400 million after tax.
Upstream net production is expected at 3.8 to 3.9 million barrels of oil-equivalent per day, reflecting downtime at Tengizchevroil and reduced Middle East output.
Treace Medical preliminarily reported first-quarter 2026 revenue of $47.0 million to $47.2 million and cash of about $51.9 million, and raised the low end of its full-year 2026 revenue guidance to $202 million to $212 million. The company also said Chief Commercial Officer Gaetano M. Guglielmino departed effective April 8, 2026, and will not be replaced, with his duties moved to existing staff and the head of sales reporting to the CEO.
Preliminary Q1 2026 revenue: $47.0 million to $47.2 million (unaudited; subject to financial closing procedures)
Cash, equivalents and marketable securities about $51.9 million at March 31, 2026, up about $3.5 million from $48.4 million at December 31, 2025
2026 revenue guidance updated to $202 million to $212 million, from $200 million to $212 million previously
Chief Commercial Officer Gaetano M. Guglielmino departed April 8, 2026; consulting agreement runs through January 31, 2027 at a monthly fee of $36,666.67
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.